NDAORALTABLETPriority Review
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
5/8 — Partial
Priority Review
VIBERZI (eluxadoline) by AbbVie is opioid mu-receptor agonists [moa]. First approved in 2015.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIBERZI (eluxadoline) is an oral mu-opioid receptor agonist approved in 2015 for irritable bowel syndrome with diarrhea (IBS-D). It works by activating mu-opioid receptors in the gastrointestinal tract to reduce bowel motility and secretion. The drug represents a targeted opioid therapy designed specifically for GI indications rather than systemic pain relief.
$60MPart D
PeakStable
6.7 years to LOEDrug is in peak revenue stage with modest Part D spending (~$60M) and 35K+ annual claims, suggesting a stable but niche franchise with smaller commercial team requirements.
Mechanism of Action
Opioid mu-Receptor Agonists
Pharmacologic Class:
mu-Opioid Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Investigation of Eluxadoline for Diabetic Diarrhea
Started Jul 2022
0Diabetic DiarrheaDiabetesDiarrhea
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Started Aug 2021
124 enrolled
Irritable Bowel Syndrome
Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence
Started Apr 2019
0Fecal IncontinenceAccidental Bowel LeakageAnal Incontinence+2 more
Eluxadoline Bile Acid Malabsorption (BAM) Study
Started Feb 2018
24 enrolled
Irritable Bowel Syndrome With Diarrhea
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
Started Nov 2017
95 enrolled
Irritable Bowel Syndrome
Worked on VIBERZI at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.